Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma

Syren, Pascal ; Andersson, Roland LU ; Bauden, Monika LU orcid and Ansari, Daniel LU (2017) In Scandinavian Journal of Gastroenterology 52(6-7). p.668-673
Abstract

Pancreatic ductal adenocarcinoma (PDAC) prognosis remains very poor and has only marginally improved during the last decades. Epigenetic alterations have been the focus of many recent studies and offer valuable options for PDAC detection, prognosis and treatment. DNA methylation, histone modifications and microRNA (miR) level changes can be used as biomarkers. These alterations occur early in carcinogenesis and may be specific for PDAC. Additionally, epigenetic alterations can be analyzed from cell-free DNA, free-circulating nucleosomes or shed tumor cells in blood. High-throughput methods are available for miR and DNA methylation level detection. In particular, multiple promising miR level changes have been discovered. No single... (More)

Pancreatic ductal adenocarcinoma (PDAC) prognosis remains very poor and has only marginally improved during the last decades. Epigenetic alterations have been the focus of many recent studies and offer valuable options for PDAC detection, prognosis and treatment. DNA methylation, histone modifications and microRNA (miR) level changes can be used as biomarkers. These alterations occur early in carcinogenesis and may be specific for PDAC. Additionally, epigenetic alterations can be analyzed from cell-free DNA, free-circulating nucleosomes or shed tumor cells in blood. High-throughput methods are available for miR and DNA methylation level detection. In particular, multiple promising miR level changes have been discovered. No single epigenetic biomarker that offers a sufficient specificity has been discovered yet, but patterns containing multiple independent biomarkers exist.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biomarkers, diagnosis, DNA methylation, epigenetics, histone modifications, microRNA, Pancreatic cancer
in
Scandinavian Journal of Gastroenterology
volume
52
issue
6-7
pages
668 - 673
publisher
Taylor & Francis
external identifiers
  • pmid:28301276
  • wos:000399808100009
  • scopus:85018657425
ISSN
0036-5521
DOI
10.1080/00365521.2017.1301989
language
English
LU publication?
yes
id
2ad5a947-4228-4a4d-9b8a-db7bf50731fb
date added to LUP
2017-06-07 15:08:48
date last changed
2024-01-13 22:18:26
@article{2ad5a947-4228-4a4d-9b8a-db7bf50731fb,
  abstract     = {{<p>Pancreatic ductal adenocarcinoma (PDAC) prognosis remains very poor and has only marginally improved during the last decades. Epigenetic alterations have been the focus of many recent studies and offer valuable options for PDAC detection, prognosis and treatment. DNA methylation, histone modifications and microRNA (miR) level changes can be used as biomarkers. These alterations occur early in carcinogenesis and may be specific for PDAC. Additionally, epigenetic alterations can be analyzed from cell-free DNA, free-circulating nucleosomes or shed tumor cells in blood. High-throughput methods are available for miR and DNA methylation level detection. In particular, multiple promising miR level changes have been discovered. No single epigenetic biomarker that offers a sufficient specificity has been discovered yet, but patterns containing multiple independent biomarkers exist.</p>}},
  author       = {{Syren, Pascal and Andersson, Roland and Bauden, Monika and Ansari, Daniel}},
  issn         = {{0036-5521}},
  keywords     = {{biomarkers; diagnosis; DNA methylation; epigenetics; histone modifications; microRNA; Pancreatic cancer}},
  language     = {{eng}},
  month        = {{07}},
  number       = {{6-7}},
  pages        = {{668--673}},
  publisher    = {{Taylor & Francis}},
  series       = {{Scandinavian Journal of Gastroenterology}},
  title        = {{Epigenetic alterations as biomarkers in pancreatic ductal adenocarcinoma}},
  url          = {{http://dx.doi.org/10.1080/00365521.2017.1301989}},
  doi          = {{10.1080/00365521.2017.1301989}},
  volume       = {{52}},
  year         = {{2017}},
}